PPAR Agonist-Induced Reduction of Mcp1 in Atherosclerotic Plaques of Obese, Insulin-Resistant Mice Depends on Adiponectin-Induced Irak3 Expression

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Hulsmans, Maarten ^a   Geeraert, Benjamine ^a   Arnould, Thierry ^b   Tsatsanis, Christos ^c   Holvoet, Paul ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b University of Namur   (Belgium)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FENOFIBRATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOACCUMULATION; CELL FUNCTION; CONTROLLED STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

ADIPOCYTES; ADIPONECTIN; ANIMALS; CHEMOKINE CCL2; DIET, HIGH-FAT; FENOFIBRATE; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LEPTIN; MACROPHAGES; MICE; MICE, INBRED C57BL; OBESITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PLAQUE, ATHEROSCLEROTIC; PPAR ALPHA; PPAR GAMMA; THIAZOLIDINEDIONES;

MUS;

EID: 84876429730     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062253     Document Type: Article

References (46)

1. Hotamisligil GS, (2006) Inflammation and metabolic disorders. Nature 444: 860-867.
2. Hulsmans M, Holvoet P, (2010) The vicious circle between oxidative stress and inflammation in atherosclerosis. J.Cell Mol.Med. 14: 70-78.
3. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J.Clin.Invest 112: 1796-1808.
4. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, et al. (2007) Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447: 1116-1120.
5. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, et al. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J.Clin.Invest 116: 1784-1792.
6. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, et al. (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J.Clin.Endocrinol.Metab 86: 3815-3819.
7. Wesche H, Gao X, Li X, Kirschning CJ, Stark GR, et al. (1999) IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. Journal of Biological Chemistry 274: 19403-19410.
8. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, et al. (2002) IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110: 191-202.
9. Zacharioudaki V, Androulidaki A, Arranz A, Vrentzos G, Margioris AN, et al. (2009) Adiponectin promotes endotoxin tolerance in macrophages by inducing IRAK-M expression. Journal of Immunology 182: 6444-6451.
10. Hulsmans M, Geeraert B, De Keyzer D, Mertens A, Lannoo M, et al. (2012) Interleukin-1 receptor-associated kinase-3 is a key inhibitor of inflammation in obesity and metabolic syndrome. PLoS.ONE. 7: e30414.
11. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, et al. (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98: 2088-2093.
12. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, et al. (2001) Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 24: 308-315.
13. Zhang LL, Gao CY, Fang CQ, Wang YJ, Gao D, et al. (2011) PPAR{gamma} attenuates intimal hyperplasia through inhibiting TLR4-mediated inflammation in vascular smooth muscle cells. Cardiovascular Research 92: 484-493.
14. Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Liapis CD, et al. (2008) Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus. Diabetic Medicine 25: 333-340.
15. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, et al. (1999) Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ.Res. 85: 394-402.
16. Mertens A, Verhamme P, Bielicki JK, Phillips MC, Quarck R, et al. (2003) Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation 107: 1640-1646.
17. Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, et al. (2004) Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 110: 3259-3269.
18. Taleb S, Herbin O, Ait-Oufella H, Verreth W, Gourdy P, et al. (2007) Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 27: 2691-2698.
19. Verreth W, De Keyzer D, Davey PC, Geeraert B, Mertens A, et al. (2007) Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice. British Journal of Pharmacology 151: 347-355.
20. Geeraert B, Crombe F, Hulsmans M, Benhabiles N, Geuns JM, et al. (2010) Stevioside inhibits atherosclerosis by improving insulin signaling and antioxidant defense in obese insulin-resistant mice. Int.J.Obes.(Lond) 34: 569-577.
21. Zamboni DS, Rabinovitch M, (2003) Nitric oxide partially controls Coxiella burnetii phase II infection in mouse primary macrophages. Infect.Immun. 71: 1225-1233.
22. Englen MD, Valdez YE, Lehnert NM, Lehnert BE, (1995) Granulocyte/macrophage colony-stimulating factor is expressed and secreted in cultures of murine L929 cells. J.Immunol.Methods 184: 281-283.
23. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, et al. (2007) PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 6: 137-143.
24. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, et al. (2002) Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB Journal 16: 1027-1040.
25. Calkin AC, Forbes JM, Smith CM, Lassila M, Cooper ME, et al. (2005) Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arteriosclerosis, Thrombosis, and Vascular Biology 25: 1903-1909.
26. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, et al. (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106: 679-684.
27. Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, et al. (2002) Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 25: 542-549.
28. Verreth W, Ganame J, Mertens A, Bernar H, Herregods MC, et al. (2006) Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice. Arteriosclerosis, Thrombosis, and Vascular Biology 26: 922-928.
29. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, et al. (2002) Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143: 998-1007.
30. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, et al. (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52: 1655-1663.
31. Padmalayam I, Suto M (2013) Role of Adiponectin in the metabolic syndrome: current perspectives on its modulation as a treatment strategy. Curr.Pharm.Des doi:CPD-EPUB-20130220-9.
32. Hu D, Fukuhara A, Miyata Y, Yokoyama C, Otsuki M, et al. (2013) Adiponectin Regulates Vascular Endothelial Growth Factor-C Expression in Macrophages via Syk-ERK Pathway. PLoS.ONE. 8: e56071.
33. Tao L, Wang Y, Gao E, Zhang H, Yuan Y, et al. (2010) Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction. Circulation Research 106: 409-417.
34. Wong WT, Tian XY, Xu A, Yu J, Lau CW, et al. (2011) Adiponectin is required for PPARgamma-mediated improvement of endothelial function in diabetic mice. Cell Metab 14: 104-115.
35. Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, et al. (2007) Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome. Atherosclerosis 195: 138-146.
36. Standiford TJ, Kuick R, Bhan U, Chen J, Newstead M, et al. (2011) TGF-beta-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth. Oncogene 30: 2475-2484.
37. Chen W, Saxena A, Li N, Sun J, Gupta A, et al. (2012) Endogenous IRAK-M Attenuates Postinfarction Remodeling Through Effects on Macrophages and Fibroblasts. Arteriosclerosis, Thrombosis, and Vascular Biology 32: 2598-2608.
38. Tsai JS, Chen CY, Chen YL, Chuang LM, (2010) Rosiglitazone inhibits monocyte/macrophage adhesion through de novo adiponectin production in human monocytes. J.Cell Biochem. 110: 1410-1419.
39. Burgos-Ramos E, Sackmann-Sala L, Baquedano E, Cruz-Topete D, Barrios V, et al. (2012) Central leptin and insulin administration modulates serum cytokine- and lipoprotein-related markers. Metabolism 61: 1646-1657.
40. de Heredia FP, Gomez-Martinez S, Marcos A, (2012) Obesity, inflammation and the immune system. Proceedings of the Nutrition Society 71: 332-338.
41. Kintscher U, Law RE, (2005) PPARgamma-mediated insulin sensitization: the importance of fat versus muscle. Am.J.Physiol Endocrinol.Metab 288: E287-E291.
42. Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, et al. (1998) Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int.J Clin.Pharmacol.Ther. 36: 345-349.
43. Chakrabarti S, Blair P, Freedman JE, (2007) CD40-40L signaling in vascular inflammation. Journal of Biological Chemistry 282: 18307-18317.
44. van der Hoogt CC, de Haan W, Westerterp M, Hoekstra M, Dallinga-Thie GM, et al. (2007) Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. Journal of Lipid Research 48: 1763-1771.
45. Srivastava RA, (2011) Evaluation of anti-atherosclerotic activities of PPAR-alpha, PPAR-gamma, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters. Atherosclerosis 214: 86-93.
46. Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, et al. (2002) Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. Journal of Biological Chemistry 277: 48051-48057.